Evidence map›Paper›PMID 40490954›Full record

ArticleClinical and translational medicine2025

The new era of siRNA therapy: Advances in cancer treatment.

Zhuan Zhang, Miaorong Yu, Guoqing Hu, Yong Gan

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. CRISPR Interference to Inhibit Oncogenes for Cancer Therapy.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Nucleic acids in medicinal plants and their pharmaceutical potential.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  4. The new era of siRNA therapy: Advances in cancer treatment.Clinical and translational medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhuan ZhangState Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Miaorong YuState Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Guoqing HuDepartment of Engineering Mechanics, State Key Laboratory of Fluid Power and Mechatronic Systems, Zhejiang University, Hangzhou, China.
Yong GanState Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID https://orcid.org/0000-0002-4579-994X

Funding

Key Technology Program for Nucleic Acid Drugs of NCTIB NCTIB2022HS01006National Key Research and Development Program of China 2022YFA1203200National Natural Science Foundation of China 82073773National Science Fund of Distinguished Young Scholars 82025032Shanghai Action Plan for Science, Technology and Innovation 23HC1401200Shanghai Institute of Materia Medica, Chinese Academy of Sciences SIMM0220232001the Key Research Program of Chinese Academy of Sciences ZDBS-ZRKJZ-TLC005the Young Elite Scientists Sponsorship Program 2022QNRC001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40490954
PMCPMC12148947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.